PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -275 Thousand EUR | 111.05% |
| 2022 | -25.26 Million EUR | -85.16% |
| 2021 | -13.64 Million EUR | 19.9% |
| 2020 | -17.03 Million EUR | 71.17% |
| 2019 | -59.08 Million EUR | 55.36% |
| 2018 | -132.35 Million EUR | 22.91% |
| 2017 | -171.68 Million EUR | -393.62% |
| 2016 | -34.78 Million EUR | 22.58% |
| 2015 | -44.92 Million EUR | -23.78% |
| 2014 | -36.29 Million EUR | -155.89% |
| 2013 | -14.18 Million EUR | -80.11% |
| 2012 | -7.87 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - EUR | -100.0% |
| 2024 Q2 | 9.4 Million EUR | 0.0% |
| 2023 Q1 | -10.87 Million EUR | 56.94% |
| 2023 FY | 2.79 Million EUR | 111.05% |
| 2023 Q3 | 25.18 Million EUR | 350.66% |
| 2023 Q4 | 2.07 Million EUR | -91.77% |
| 2023 Q2 | -10.04 Million EUR | 7.61% |
| 2022 Q2 | -30.79 Million EUR | -191.37% |
| 2022 Q1 | 33.7 Million EUR | 347.06% |
| 2022 Q3 | 54.04 Million EUR | 275.5% |
| 2022 Q4 | -25.26 Million EUR | -146.74% |
| 2021 Q1 | 44.45 Million EUR | 360.99% |
| 2021 Q2 | -21.09 Million EUR | -147.45% |
| 2021 Q4 | -13.64 Million EUR | 0.0% |
| 2020 Q2 | -28.95 Million EUR | -139.57% |
| 2020 Q1 | 73.18 Million EUR | 223.86% |
| 2020 Q4 | -17.03 Million EUR | 0.0% |
| 2019 Q3 | -68.45 Million EUR | 18.37% |
| 2019 Q4 | -59.08 Million EUR | 13.68% |
| 2019 Q2 | -83.85 Million EUR | -162.4% |
| 2019 Q1 | 134.37 Million EUR | 201.5% |
| 2018 Q4 | -132.39 Million EUR | 0.0% |
| 2018 Q2 | -163.05 Million EUR | -187.89% |
| 2018 Q1 | 185.52 Million EUR | 201.51% |
| 2017 Q4 | -182.76 Million EUR | 0.0% |
| 2017 Q1 | 37.64 Million EUR | 208.08% |
| 2017 Q2 | -85.39 Million EUR | -326.83% |
| 2016 Q2 | -35.86 Million EUR | -178.58% |
| 2016 Q1 | 45.63 Million EUR | 201.45% |
| 2016 Q4 | -34.83 Million EUR | 0.0% |
| 2016 Q3 | -34.83 Million EUR | 2.87% |
| 2015 Q2 | -30.39 Million EUR | 0.0% |
| 2015 Q1 | -30.39 Million EUR | 16.26% |
| 2015 Q3 | -44.98 Million EUR | -48.0% |
| 2015 Q4 | -44.98 Million EUR | 0.0% |
| 2014 Q4 | -36.29 Million EUR | 0.0% |
| 2014 Q2 | -11.39 Million EUR | 0.0% |
| 2014 Q1 | -11.39 Million EUR | 19.65% |
| 2014 Q3 | -36.29 Million EUR | -218.45% |
| 2013 Q3 | -14.18 Million EUR | 0.0% |
| 2013 Q1 | 7.87 Million EUR | 200.0% |
| 2013 Q4 | -14.18 Million EUR | 0.0% |
| 2012 Q4 | -7.87 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 99.544% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 101.29% |
| Vetoquinol SA | -129.83 Million EUR | 99.788% |
| Valneva SE | 82.73 Million EUR | 100.332% |
| AB Science S.A. | 13.03 Million EUR | 102.11% |
| Nanobiotix S.A. | -29.8 Million EUR | 99.077% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 98.515% |
| BioSenic S.A. | 28.04 Million EUR | 100.981% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 99.86% |
| Formycon AG | 2.45 Million EUR | 111.22% |